a maverick drugs industry entrepreneur may prove detractors wrong cancer drug appears good existing treatments without severe sideeffects the drug submitted regulatory approval first quarter 1995 could sale europe 1996 dr david horrobins company scotia pharmaceuticals yesterday published finalstage clinical trial results ef13 pancreatic cancer drug show life expectancy cancer sufferers increased twothirds compared patients chemotherapy shares scotia pharmaceuticals rose 21p 274p company presented results city analysts with price rise scotia become uks second biggest biotechnology company market capitalisation cancer experts gave results cautious welcome professor gordon mcvie scientific director cancer research campaign londonbased charity said results encouraging but pointed trials compared ef13 historic data mortality would convincing drug compared placebo neither doctor patient knew administered scotia said promising preliminary trial data meant ethical problems knowingly withholding drug sufferers professor karol sikora cancer consultant hammersmith hospital london said results interesting much evaluation needed cancer pancreas one deadliest forms disease 60000 deaths year europe north america the historic data suggest normal treatment regime uk average life expectancy three months with intensive chemotherapy sometimes used us figure seven months with high doses ef13 patients survived year average as trial placebocontrolled possible patients ef13 survived longer selected stronger doctors gave extra attention success drug would vindicate dr horrobins championing obscure corner chemistry dealing fatty acids normally drug research based protein chemistry the former professor medicine montreal university began selling evening primrose oil natural source fatty acids health food shops used profits establish research centres manufacturing plants nova scotia canada western isles scotland he developed three drugs treating skin conditions